



**KP TISSUE INC.**

**UNAUDITED CONDENSED FINANCIAL STATEMENT  
FOR THE 13-WEEK PERIODS ENDED MARCH 29, 2015  
AND MARCH 30, 2014**

**KP Tissue Inc.**  
**Unaudited Condensed Statement of Financial Position**

(tabular amounts are in thousands of Canadian dollars)

	<b>March 29, 2015</b>	<b>December 31, 2014</b>
	<b>\$</b>	<b>\$</b>
<b>Assets</b>		
<b>Current assets</b>		
Distributions receivable	1,603	1,601
<b>Non-current assets</b>		
Investment in associate (note 5)	151,011	153,732
<b>Total Assets</b>	<u>152,614</u>	<u>155,333</u>
<b>Liabilities</b>		
<b>Current liabilities</b>		
Dividend payable	1,603	1,601
Payable to Partnership	48	53
Advances from Partnership (note 6)	219	584
Income taxes payable	82	495
	<u>1,952</u>	<u>2,733</u>
<b>Non-current liabilities</b>		
Deferred income taxes (note 6)	1,593	2,005
<b>Total liabilities</b>	<u>3,545</u>	<u>4,738</u>
<b>Equity</b>		
Common shares (note 7)	10,341	10,138
Contributed surplus	144,819	144,819
Deficit	(17,324)	(12,220)
Accumulated other comprehensive income	11,233	7,858
<b>Total equity</b>	<u>149,069</u>	<u>150,595</u>
<b>Total liabilities and equity</b>	<u>152,614</u>	<u>155,333</u>
<b>Subsequent events (note 7)</b>		

The accompanying notes are an integral part of these condensed financial statements.

**KP Tissue Inc.**  
**Unaudited Condensed Statement of Comprehensive Income (Loss)**

For the 13-week periods ended March 29, 2015 and March 30, 2014

(tabular amounts are in thousands of Canadian dollars, except share and per share amounts )

	13-week period ended March 29, 2015 \$	13-week period ended March 30, 2014 \$
<b>Equity loss (note 5)</b>	(658)	(2,083)
<b>Dilution gain (note 7)</b>	85	44
<b>Loss before income taxes</b>	(573)	(2,039)
<b>Income taxes (note 6)</b>	64	(357)
<b>Net loss for the period</b>	(637)	(1,682)
<b>Other comprehensive income (loss) net of tax expense (recovery) (note 8)</b>		
<b>Items that will not be reclassified to net loss:</b>		
Remeasurements of pensions	(2,495)	157
Remeasurements of post-retirement benefits	(367)	(123)
<b>Items that may be subsequently reclassified to net loss:</b>		
Available-for-sale investment	(36)	(4)
Cumulative translation adjustment	3,411	2,049
<b>Total other comprehensive income for the period</b>	513	2,079
<b>Comprehensive income (loss) for the period</b>	(124)	397
<b>Basic loss per share</b>	(0.07)	(0.19)
<b>Weighted average number of shares outstanding</b>	8,871,820	8,805,820

The accompanying notes are an integral part of these condensed financial statements.

**KP Tissue Inc.**  
**Unaudited Condensed Statement of Changes in Equity**

For the 13-week periods ended March 29, 2015 and March 30, 2014

(tabular amounts are in thousands of Canadian dollars, except share amounts)

	Common shares		Contributed surplus \$	Retained earnings (deficit) \$	Accumulated other comprehensive income \$	Total equity \$
	#	\$				
<b>As of January 1, 2014</b>	8,792,974	9,068	144,819	709	3,375	157,971
Issuance of common shares	15,244	253	-	-	-	253
Dividends payable	-	-	-	(1,585)	-	(1,585)
Remeasurements of pensions	-	-	-	157	-	157
Remeasurements of post-retirement benefits	-	-	-	(123)	-	(123)
Available-for-sale investment	-	-	-	-	(4)	(4)
Cumulative translation adjustment	-	-	-	-	2,049	2,049
Net loss for the period	-	-	-	(1,682)	-	(1,682)
<b>As of March 30, 2014</b>	<b>8,808,218</b>	<b>9,321</b>	<b>144,819</b>	<b>(2,524)</b>	<b>5,420</b>	<b>157,036</b>
<b>As of January 1, 2015</b>	8,861,979	10,138	144,819	(12,220)	7,858	150,595
Issuance of common shares (note 7)	11,863	195	-	-	-	195
Dividends payable	-	-	-	(1,597)	-	(1,597)
Fair value adjustment (note 7)	-	8	-	(8)	-	-
Remeasurements of pensions	-	-	-	(2,495)	-	(2,495)
Remeasurements of post-retirement benefits	-	-	-	(367)	-	(367)
Available-for-sale investment	-	-	-	-	(36)	(36)
Cumulative translation adjustment	-	-	-	-	3,411	3,411
Net loss for the period	-	-	-	(637)	-	(637)
<b>As of March 29, 2015</b>	<b>8,873,842</b>	<b>10,341</b>	<b>144,819</b>	<b>(17,324)</b>	<b>11,233</b>	<b>149,069</b>

The accompanying notes are an integral part of these condensed financial statements.

**KP Tissue Inc.**  
**Unaudited Condensed Statement of Cash Flows**  
**For the 13-week periods ended March 29, 2015 and March 30, 2014**

(tabular amounts are in thousands of Canadian dollars)

	<b>13-week period ended March 29, 2015</b>	<b>13-week period ended March 30, 2014</b>
	\$	\$
<b>Cash flows from (used in) operating activities</b>		
Net loss for the period	(637)	(1,682)
Items not affecting cash		
Equity loss	658	2,083
Dilution gain	(85)	(44)
Income taxes	64	(357)
Total items not affecting cash	637	1,682
Tax payments	(790)	(459)
Tax distribution received	571	459
Advances received	219	-
<b>Net cash from (used in) operating activities</b>	<b>-</b>	<b>-</b>
<b>Cash flows from (used in) investing activities</b>		
Investment in associate (note 5)	(195)	(253)
Partnership unit distributions received	1,595	1,583
<b>Net cash from investing activities</b>	<b>1,400</b>	<b>1,330</b>
<b>Cash flows from (used in) financing activities</b>		
Issuance of common shares (note 7)	195	253
Dividends paid	(1,595)	(1,583)
<b>Net cash used in financing activities</b>	<b>(1,400)</b>	<b>(1,330)</b>
<b>Increase (decrease) in cash and cash equivalents during the period</b>	<b>-</b>	<b>-</b>
<b>Cash and cash equivalents - Beginning of period</b>	<b>-</b>	<b>-</b>
<b>Cash and cash equivalents - End of period</b>	<b>-</b>	<b>-</b>

The accompanying notes are an integral part of these condensed financial statements.

# **KP Tissue Inc.**

## **Notes to Unaudited Condensed Financial Statements**

**For the 13-week periods ended March 29, 2015 and March 30, 2014**

---

(tabular amounts are in thousands of Canadian dollars, except share amounts)

### **1 General information**

KP Tissue Inc. (KPT or the Corporation) was incorporated by articles of incorporation under the Canadian Business Corporations Act on October 1, 2012. As of March 29, 2015, the Corporation held a 16.5% (December 31, 2014 – 16.5%), interest in Kruger Products L.P. (KPLP or the Partnership), whose principal business is to produce, distribute, market and sell a wide range of disposable tissue products, including bathroom tissue, facial tissue, paper towels and napkins for both the consumer and away-from-home markets in North America. The Corporation's headquarters are located in Mississauga, Ontario, Canada.

### **2 Basis of presentation**

The condensed financial statements have been prepared in accordance with International Financial Reporting Standards, applicable to the preparation of interim financial statements, including International Accounting Standards (IAS) 34 – Interim Financial Reporting as issued by the International Accounting Standards Board (IASB), and with interpretations of the International Financial Reporting Committee which the Canadian Accounting Standards Board has approved for incorporation into Part 1 of the CPA Canada Handbook - Accounting. The condensed financial statements should be read in conjunction with the financial statements for the year ended December 31, 2014. The condensed financial statements were approved for issuance by the board of directors on May 6, 2015.

### **3 Summary of significant accounting policies**

The significant accounting policies that have been used in the preparation of these condensed financial statements are described in the annual financial statements of KPT for the year ended December 31, 2014 and have been applied to all periods presented.

The impact of new standards, amendments to standards and interpretations that have been issued but not yet effective for financial periods beginning on or after January 1, 2016 and have not been early adopted have been discussed in the annual financial statements for the year ended December 31, 2014, except for the following:

- (i) IAS 34 Interim Financial Reporting. The IASB has issued an amendment to clarify what is meant by “information disclosed elsewhere in the interim financial report”. IASB prescribes the minimum content for an interim financial report, and the principles for recognition and measurement in complete and condensed financial statements for an interim period. Management is evaluating the standard and has not yet determined the impact on its unaudited condensed interim financial statements.

### **4 Critical accounting estimates and judgments**

The preparation of these unaudited condensed interim financial statements in conformity with IFRS requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities in the unaudited condensed interim financial statements and the disclosure of contingencies at the dates of the unaudited condensed interim statement of financial position, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The estimates and judgments applied by management that most significantly affect the unaudited condensed interim financial statements are the same as the ones that applied to the audited financial statements for the year ended December 31, 2014.

**KP Tissue Inc.**  
**Notes to Unaudited Condensed Financial Statements**  
**For the 13-week periods ended March 29, 2015 and March 30, 2014**

(tabular amounts are in thousands of Canadian dollars, except share amounts)

**5 Investment in associate**

Changes in the carrying amount of the investment were as follows:

	<b>13-week period ended March 29, 2015</b>	<b>Year ended December 31, 2014</b>
	<b>\$</b>	<b>\$</b>
Opening balance	153,732	161,584
Investment in associate	195	1,070
Share of income	776	3,500
Depreciation of fair value increments	(1,434)	(5,879)
Share of other comprehensive income	409	307
Dilution gain	85	102
Tax Distribution	(1,155)	(584)
Partnership unit distributions	(1,597)	(6,368)
Closing balance	<u>151,011</u>	<u>153,732</u>

The equity loss was comprised of the following components:

	<b>13-week period ended March 29, 2015</b>	<b>13-week period ended March 30, 2014</b>
	<b>\$</b>	<b>\$</b>
Share of income (loss)	776	(538)
Depreciation of fair value increments	(1,434)	(1,545)
	<u>(658)</u>	<u>(2,083)</u>

The following summarizes financial information about the assets, liabilities, revenue and net income of KPLP, in which the Corporation holds a 16.5% interest (December 31, 2014 – 16.5%). The financial information was derived from the condensed consolidated financial statements of KPLP for the 13-week period ended March 29, 2015. The assets and liabilities disclosed include the fair value adjustments made to the carrying amount of the assets and liabilities of the associate on its acquisition.

**KP Tissue Inc.**  
**Notes to Unaudited Condensed Financial Statements**

For the 13-week periods ended March 29, 2015 and March 30, 2014

(tabular amounts are in thousands of Canadian dollars, except share amounts)

	<b>March 29, 2015</b>		
	<b>KPLP basis of accounting</b>	<b>FV increment</b>	<b>KPT basis of accounting</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>
Current assets	311,691	-	311,691
Non-current assets	904,329	577,767	1,482,096
Liabilities to non-unitholders	744,229	8,212	752,441
Partnership units liability	122,486	-	122,486
Net assets	349,305		
	<b>13-week period ended March 29, 2015</b>		
	<b>\$</b>		
Revenue	265,376		
Net income	4,710		
Other comprehensive income	2,568		
Total comprehensive income	7,278		
	<b>December 31, 2014</b>		
	<b>KPLP basis of accounting</b>	<b>FV increment</b>	<b>KPT basis of accounting</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>
Current assets	321,636	-	321,636
Non-current assets	870,365	586,516	1,456,881
Liabilities to non-unitholders	716,375	8,800	725,175
Partnership units liability	128,123	-	128,123
Net assets	347,503		
	<b>13-week period ended March 30, 2014</b>		
	<b>\$</b>		
Revenue	234,608		
Net loss	(3,223)		
Other comprehensive income	11,015		
Total comprehensive income	7,792		



**KP Tissue Inc.**  
**Notes to Unaudited Condensed Financial Statements**  
**For the 13-week periods ended March 29, 2015 and March 30, 2014**

(tabular amounts are in thousands of Canadian dollars, except share amounts)

The following shows the reconciliation of KPT's portion of KPLP equity to the investment recorded in KPT:

	<b>March 29, 2015</b>	<b>December 31, 2014</b>
	<b>\$</b>	<b>\$</b>
KPLP consolidated equity	349,305	347,503
Add back: Inception value of Partnership units liability	118,562	118,562
Less: Equity pertaining to Kruger Inc. and KPGP	<u>(313,678)</u>	<u>(311,673)</u>
Equity pertaining to KPT	154,189	154,392
Investment in associate recorded in KPT	<u>151,011</u>	<u>153,732</u>
Reconciling difference	3,178	660
Reconciling items since inception:		
Equity issuance costs	(11,110)	(11,110)
Depreciation of FV increments	15,576	14,142
Currency translation adjustment in fair value increments	(2,225)	(2,239)
Tax distribution	1,739	584
Gain on exercise of overallotment option	(375)	(375)
Dilution gain	<u>(427)</u>	<u>(342)</u>
	<u>-</u>	<u>-</u>

With respect to KPT's investment in KPLP, KPT does not have any guarantees, or contractual obligations for KPLP's borrowing arrangements.

**6 Income taxes**

The Corporation is required to pay income tax on its share of the taxable income of KPLP. The Corporation has not recognized at the date of acquisition the deferred tax assets and liabilities related to the differences between the accounting and tax basis of KPLP's assets and liabilities. Accordingly, the Corporation is tracking the temporary differences that were subject to the initial recognition exemption and recognizes newly created temporary differences as they arise.

The major components of income taxes recognized in the statement of comprehensive income (loss) were as follows:

	<b>13-week period ended March 29, 2015</b>	<b>13-week period ended March 30, 2014</b>
	<b>\$</b>	<b>\$</b>
Current tax expense (recovery)	372	(35)
Deferred tax credit	<u>(308)</u>	<u>(322)</u>
	<u>64</u>	<u>(357)</u>

**KP Tissue Inc.**  
**Notes to Unaudited Condensed Financial Statements**  
**For the 13-week periods ended March 29, 2015 and March 30, 2014**

(tabular amounts are in thousands of Canadian dollars, except share amounts)

Details of the provision for income taxes were as follows:

	<b>13-week period ended March 29, 2015</b>	<b>13-week period ended March 20, 2014</b>
	<b>\$</b>	<b>\$</b>
Income tax at statutory rate of 26%	(149)	(530)
Permanent differences and other	80	52
Dilution gain	(22)	(12)
Taxed in hands of subsidiaries	4	115
Realization of previously unrecognized tax attributes	404	266
Change in basis of investment in associate	(253)	(248)
	<u>64</u>	<u>(357)</u>

Components of the deferred income tax liability were as follows:

	<b>March 29, 2015</b>	<b>December 31, 2014</b>
	<b>\$</b>	<b>\$</b>
Deferred tax liability		
Investment in associate	551	751
Pensions	(432)	(267)
Deferred finance fees	-	(36)
Property, plant and equipment	2,290	2,226
Other	(816)	(669)
	<u>1,593</u>	<u>2,005</u>

The analysis of the deferred tax liability was as follows:

	<b>March 29, 2015</b>	<b>December 31, 2014</b>
	<b>\$</b>	<b>\$</b>
Deferred tax liabilities to be realized greater than 12 months	<u>1,593</u>	<u>2,005</u>
	<u>1,593</u>	<u>2,005</u>

**KP Tissue Inc.**  
**Notes to Unaudited Condensed Financial Statements**  
**For the 13-week periods ended March 29, 2015 and March 30, 2014**

(tabular amounts are in thousands of Canadian dollars, except share amounts)

The movement in the deferred tax liability was as follows:

	<b>March 29, 2015</b>	<b>December 31, 2014</b>
	<u>\$</u>	<u>\$</u>
Opening balance	2,005	3,033
Charge to net loss	(308)	(895)
Charge to other comprehensive income		
- remeasurements of cumulative translation adjustment	509	669
Charge to other comprehensive income		
- remeasurements of post-retirement benefits	(235)	(225)
Charge to other comprehensive income		
- remeasurements of pensions	(373)	(577)
Charge to other comprehensive income		
- mark-to-market on Available-for-sale investment	(5)	-
	<u>1,593</u>	<u>2,005</u>

On February 28, 2014, KPT received a Tax Distribution of \$0.6 million from KPLP for purposes of settling its obligations for federal and provincial taxes.

For the 13-week period ended March 29, 2015, pursuant to the Tax Distribution as defined in the Partnership Agreement, KPT received an advance from KPLP of \$0.2 million to pay the monthly tax instalments. The advance is non-interest bearing and non-recourse and will be settled when the Tax Distribution is declared annually. On February 27, 2015, KPT received a tax distribution of \$1.2 million from KPLP for purposes of settling its obligation for federal and provincial taxes, for fiscal 2014.

**7 Dividends**

On January 15, 2015, the Corporation paid a dividend of \$0.18 per common share to shareholders. Pursuant to the Corporation's Dividend Reinvestment Plan (DRIP), a portion of the dividend was reinvested by the shareholders, resulting in the Corporation issuing 11,863 common shares at a price of \$16.46. The proceeds were used to acquire additional units of KPLP.

On April 15, 2015, the Corporation paid a dividend of \$0.18 per common share to shareholders. Pursuant to the Corporation's DRIP, a portion of the dividend was reinvested by the shareholders, resulting in the Corporation issuing 24,933 common shares at a price of \$15.56.

Subsequent to March 29, 2015, the Corporation declared a dividend of \$0.18 per common share to shareholders, payable on July 15, 2015.

As a result of the DRIP and Kruger's reinvestment of its distribution from KPLP in units of KPLP, a dilution gain of \$0.09 million was recorded in the period ended March 29, 2015.

**KP Tissue Inc.**  
**Notes to Unaudited Condensed Financial Statements**  
**For the 13-week periods ended March 29, 2015 and March 30, 2014**

(tabular amounts are in thousands of Canadian dollars, except share amounts)

**8 Income tax recovery (expense) on other comprehensive income (loss)**

Income tax recovery (expense) on other comprehensive income (loss) was as follows:

	<b>13-week period ended March 29, 2015</b>	<b>13-week period ended March 30, 2014</b>
	<b>\$</b>	<b>\$</b>
<b>Items that will not be reclassified to net loss:</b>		
Remeasurements of pensions	(2,868)	180
Income tax recovery (expense)	373	(23)
Net of income tax recovery (expense)	<u>(2,495)</u>	<u>157</u>
Remeasurements of post-retirement benefits	(602)	(141)
Income tax recovery	235	18
Net of income tax recovery	<u>(367)</u>	<u>(123)</u>
<b>Items that may be subsequently reclassified to net loss:</b>		
Available-for-sale investment	(41)	(5)
Income tax recovery	5	1
Net of income tax recovery	<u>(36)</u>	<u>(4)</u>
Cumulative translation adjustment	3,920	2,356
Income tax expense	(509)	(307)
Net of income tax expense	<u>3,411</u>	<u>2,049</u>